<code id='AC2E2DA425'></code><style id='AC2E2DA425'></style>
    • <acronym id='AC2E2DA425'></acronym>
      <center id='AC2E2DA425'><center id='AC2E2DA425'><tfoot id='AC2E2DA425'></tfoot></center><abbr id='AC2E2DA425'><dir id='AC2E2DA425'><tfoot id='AC2E2DA425'></tfoot><noframes id='AC2E2DA425'>

    • <optgroup id='AC2E2DA425'><strike id='AC2E2DA425'><sup id='AC2E2DA425'></sup></strike><code id='AC2E2DA425'></code></optgroup>
        1. <b id='AC2E2DA425'><label id='AC2E2DA425'><select id='AC2E2DA425'><dt id='AC2E2DA425'><span id='AC2E2DA425'></span></dt></select></label></b><u id='AC2E2DA425'></u>
          <i id='AC2E2DA425'><strike id='AC2E2DA425'><tt id='AC2E2DA425'><pre id='AC2E2DA425'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:fashion    Page View:4797
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In